Evidence map›Paper›PMID 40202761›Full record

ArticleJAMA network open2025

Symptomatic Necrosis With Dual Immune-Checkpoint Inhibition and Radiosurgery for Brain Metastases.

Eugene J Vaios, Rachel F Shenker, Peter G Hendrickson, Zihan Wan, Donna Niedzwiecki, David Carpenter, Warren Floyd, Sebastian F Winter, Helen A Shih, Jorg Dietrich and 9 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eugene J VaiosDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Rachel F ShenkerDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Peter G HendricksonDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Zihan WanDuke Cancer Institute Biostatistics, Duke University Medical Center, Durham, North Carolina.
Donna NiedzwieckiDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
David CarpenterDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Warren FloydDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
Sebastian F WinterDivision of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston.
Helen A ShihDepartment of Radiation Oncology, Massachusetts General Hospital, Boston.
Jorg DietrichDivision of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston.
Chunhao WangDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
April K S SalamaDivision of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Jeffrey M ClarkeDivision of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Karen AllenDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Paul SperdutoDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Trey MullikinDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
John P KirkpatrickDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Scott R FloydDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Zachary J ReitmanDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Funding

Duke Radiation Oncology and Radiology Stimulating Access to Research in ResidencyR38CA245204 · NCI · DUKE UNIVERSITY · PI FLOYD, SCOTT R · 2020 to 2023
$1.4M
Enhancing the efficacy of Radiation Therapy for brainstem glioma by targeting ATMK08CA256045 · NCI · DUKE UNIVERSITY · PI Zachary Reitman · 2022 to 2026
$1.1M
Cell-Free DNA Methylation Patterns as a Biomarker for Tumor Biology and Clinical Outcomes for Glioblastoma PatientsK38CA292995 · NCI · DUKE UNIVERSITY · PI Eugene Vaios · 2024 to 2026
$276k
NCI NIH HHS K08 CA256045NCI NIH HHS K38 CA292995NCI NIH HHS R38 CA245204
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40202761
PMCPMC11983232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.